Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...

The FDA said in a statement that it had determined that one of the two approved vaccines, Ixchiq (Valneva SE), which contains a live, weakened version of the chikungunya virus, was responsible for 21 ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

In a U-turn from a decision two weeks ago, the FDA – citing new safety events – said the vaccine is a "danger to health".

The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...

US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

Investing.com -- Valneva SE ADR (NASDAQ:VALN) stock tumbled 20.4% premarket Monday after the U.S. Food and Drug ...